BeiGene started at overweight at Morgan Stanley on Brukinsa market share growth

by


Wall Street sign, New York City, USA

mbbirdy

  • Morgan Stanley has initiated coverage of BeiGene (NASDAQ:BGNE) at overweight saying that the pharma’s key drug Brukinsa (zanubrutinib) is taking over a larger share of the Bruton Tyrosine Kinase inhibitors (BTKi) market.
  • The investment bank set a $300 price target (~40% upside based


Leave a Comment